By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Company, Ltd. 

4-6-10 Koishikawa, Bunkyo-ku

Tokyo    112-8088  Japan
Phone: 81-3-3817-3700 Fax: n/a


SEARCH JOBS


Key Statistics


Email: webmaster@eisai.co.jp
Ownership: Public

Web Site: Eisai Company
Employees: 7,043
Symbol: ESALY.PK
 





Collaborations

IDEC Pharma 

BioVeris Corporation 





Company News
Eisai Company (ESALY.PK) Presents Results Of Phase III Clinical Study Of Lenvima (Lenvatinib) In Unresectable Hepatocellular Carcinoma At 11th ILCA Annual Conference 9/19/2017 10:27:53 AM
Eisai Company (ESALY.PK) Selected For Fifth Consecutive Year Of Membership In Dow Jones Sustainability Asia Pacific Index 2017 9/14/2017 9:37:59 AM
Eisai Company (ESALY.PK) Presents Results Of Phase Ib/II Clinical Study Of Lenvima (Lenvatinib) In Combination With Pembrolizumab For Renal Cell Carcinoma In Oral Session At ESMO 2017 Congress 9/13/2017 10:17:10 AM
Eisai Company (ESALY.PK) And Mamorio To Jointly Launch "Me-Mamorio" Tracking Tool To Support People With Dementia And Seniors Going Out 9/13/2017 9:07:24 AM
Eisai Company (ESALY.PK) Signs Agreement With Merck & Co. (MRK) To Expand Enrollment Of Study For Halaven (Eribulin) And Pembrolizumab Combination Due To Encouraging Initial Data In Triple-Negative Breast Cancer 9/6/2017 6:53:58 AM
Eisai Company (ESALY.PK) Submits Simultaneous Applications In The United States And Europe For Lenvatinib In Hepatocellular Carcinoma 7/26/2017 10:40:25 AM
MPI: Oncology Venture And Eisai Company (ESALY.PK) Forge Exclusive Global License Agreement For Clinical Stage Oncology Drug PARP Inhibitor E7449 - 2X-121 7/7/2017 10:05:46 AM
Wellness Open Living Labs. LLC, Co-Founded By Eisai Company (ESALY.PK) And Osaka City University Conclude Basic Collaboration Agreement Aimed At Solving Health Problems 7/5/2017 11:14:15 AM
Eisai Company (ESALY.PK) And Ewopharma Announce Commercial Partnership In Central Eastern Europe For Halaven, Targretin And Zonegran 6/23/2017 8:21:36 AM
Eisai Company (ESALY.PK) To Present Results Of Phase Ib/II Study Of Anticancer Agent Lenvima (Lenvatinib) In Combination With Anti-PD-1 Antibody Pembrolizumab 6/5/2017 5:03:03 PM
12345678910...
//-->